{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:24:45Z","timestamp":1792697085173,"version":"4.5.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>IMPORTANCE:<\/jats:title>\n            <jats:p>COVID-19 can cause serious illness requiring multimodal treatment and is associated with secondary infections. Studies have suggested an increased risk of fungal infections, including candidemia following severe COVID-19 though understanding of risk factors and clinical outcomes remains unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>To describe clinical characteristics, outcomes and risk factors of candidemia among patients hospitalized with severe COVID-19.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN, SETTING, AND PARTICIPANTS:<\/jats:title>\n            <jats:p>A multicenter, case-control study of patients with severe COVID-19 was conducted to evaluate risk factors and clinical outcomes in patients who developed candidemia between August 2020 and August 2021.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOMES AND MEASURES:<\/jats:title>\n            <jats:p>Chart review evaluating institutional and patient demographics, clinical and mycological characteristics, concomitant interventions (antibiotics, immunosuppressive agents, parenteral nutrition, degree of oxygen support, mechanical ventilation, surgery), treatment regimens, and outcomes (length of stay and discharge disposition)<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>A total of 275 patients were enrolled in the study, including 91 patients with severe COVID-19 and subsequent candidemia and 184 with severe COVID-19 without candidemia. Most patients received antibiotics prior to candidemia episode (93%), while approximately one-quarter of patients received biologic for COVID-19. In-hospital mortality was significantly higher in the cases compared with the controls (68% vs 40%; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.01). <jats:italic toggle=\"yes\">Candida albicans<\/jats:italic> was the most common (53%), followed by <jats:italic toggle=\"yes\">C. glabrata<\/jats:italic> (19%). Use of central lines, biologic, and paralytics were independent risk factors for candidemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS AND RELEVANCE:<\/jats:title>\n            <jats:p>Candidemia following COVID-19 infection is a concern that requires clinical consideration and patient monitoring. Risk factors for the development of candidemia in the setting of COVID-19 infection are largely consistent with traditional risk factors for candidemia in hospitalized patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000762","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T21:00:05Z","timestamp":1663102805000},"page":"e0762","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19"],"prefix":"10.1097","volume":"4","author":[{"given":"Deepali","family":"Dixit","sequence":"first","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polly","family":"Jen","sequence":"additional","affiliation":[{"name":"Newark Beth Israel Medical Center, Newark, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler D.","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Touro College of Pharmacy, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Smoke","sequence":"additional","affiliation":[{"name":"Cooperman Barnabas Medical Center, Livingston, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Andrew","family":"McCracken","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cardinale-King","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Haribhakti","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purvi","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eris","family":"Cani","sequence":"additional","affiliation":[{"name":"Touro College of Pharmacy, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seohyun (Claudia)","family":"Choi","sequence":"additional","affiliation":[{"name":"University of Washington, School of Pharmacy, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugeet","family":"Jagpal","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilly","family":"Varughese","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis L.","family":"Tatem","sequence":"additional","affiliation":[{"name":"SUNY Downstate Medical Center, Brooklyn, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanaya","family":"Bhowmick","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1016\/S2666-5247(21)00090-2","article-title":"Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: A multicentre, prospective cohort study.","volume":"2","author":"Russell","year":"2021","journal-title":"Lancet Microbe"},{"key":"R4-20240807","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.cmi.2020.07.016","article-title":"Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis.","volume":"26","author":"Langford","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/jmv.26441","article-title":"Bacterial infections and patterns of antibiotic use in patients with COVID-19.","volume":"93","author":"Goncalves Mendes Neto","year":"2021","journal-title":"J Med Virol"},{"key":"R6-20240807","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmi.2020.07.041","article-title":"Incidence of co-infections and superinfections in hospitalized patients with COVID-19: A retrospective cohort study.","volume":"27","author":"Garcia-Vidal","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"ofab510","DOI":"10.1093\/ofid\/ofab510","article-title":"Coronavirus disease 2019-associated invasive fungal infection.","volume":"8","author":"Baddley","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/civ1194","article-title":"Executive summary: Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America.","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R9-20240807","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4103\/2141-9248.113669","article-title":"Fungal infections in intensive care unit: Challenges in diagnosis and management.","volume":"3","author":"Bajwa","year":"2013","journal-title":"Ann Med Health Sci Res"},{"key":"R10-20240807","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: Nonparametric preprocessing for parametric causal inference.","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Soft"},{"key":"R14-20240807","article-title":"DescTools: Tools for Descriptive Statistics. R package version 0.99.43.","author":"Andri et mult. al.","year":"2021"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.idc.2016.07.008","article-title":"Nosocomial fungal infections: Epidemiology, infection control, and prevention.","volume":"30","author":"Suleyman","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"R16-20240807","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/321811","article-title":"Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey.","volume":"33","author":"Blumberg","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R17-20240807","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/jof8010058","article-title":"Fungal infections other than invasive aspergillosis in COVID-19 patients.","volume":"8","author":"Basile","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"R18-20240807","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: An epidemiologic meta-analysis.","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"R19-20240807","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/jof7110921","article-title":"Invasive fungal infections complicating COVID-19: A narrative review.","volume":"7","author":"Casalini","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"R20-20240807","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/cid\/ciab562","article-title":"The landscape of candidemia during the coronavirus disease 2019 (COVID-19) pandemic.","volume":"74","author":"Seagle","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R21-20240807","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/myc.13332","article-title":"Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients.","volume":"64","author":"Kayaaslan","year":"2021","journal-title":"Mycoses"},{"key":"R22-20240807","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/myc.13225","article-title":"Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic.","volume":"64","author":"Nucci","year":"2021","journal-title":"Mycoses"},{"key":"R23-20240807","first-page":"e449","article-title":"Burden of candidemia in the United States, 2017.","volume":"71","author":"Tsay","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R24-20240807","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1017\/ice.2020.368","article-title":"Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge.","volume":"42","author":"Nori","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R25-20240807","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cmi.2020.10.021","article-title":"Secondary infections in patients hospitalized with COVID-19: Incidence and predictive factors.","volume":"27","author":"Ripa","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R26-20240807","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10096-020-04142-w","article-title":"Nosocomial infections associated to COVID-19 in the intensive care unit: Clinical characteristics and outcome.","volume":"40","author":"Bardi","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R27-20240807","doi-asserted-by":"crossref","first-page":"56","DOI":"10.15585\/mmwr.mm7002e3","article-title":"Candida auris outbreak in a COVID-19 specialty care unit - Florida, July-August 2020.","volume":"70","author":"Prestel","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R28-20240807","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3201\/eid2611.203504","article-title":"Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April-July 2020.","volume":"26","author":"Chowdhary","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"R29-20240807","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cmi.2020.12.030","article-title":"Outbreak of Candida auris infection in a COVID-19 hospital in Mexico.","volume":"27","author":"Villanueva-Lozano","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R30-20240807","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40121-021-00477-9","article-title":"Impact of inflammatory response modifiers on the incidence of hospital-acquired infections in patients with COVID-19.","volume":"10","author":"Meira","year":"2021","journal-title":"Infect Dis Ther"},{"key":"R31-20240807","doi-asserted-by":"crossref","first-page":"102564","DOI":"10.1016\/j.autrev.2020.102564","article-title":"Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: An increased risk for candidemia?","volume":"19","author":"Antinori","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R32-20240807","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/mmy\/myab056","article-title":"Clinical characteristics and risk factors for COVID-19-associated Candidemia.","volume":"59","author":"Omrani","year":"2021","journal-title":"Med Mycol"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T14:14:21Z","timestamp":1723040061000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000762","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}